



## Gad Getz, PhD

Director, Cancer Genome Computational  
Analysis group  
Broad Institute of MIT and Harvard;  
Professor of Pathology, MGH

 **TECHNION**  
Israel Institute  
of Technology

  
Rappaport  
Technion Integrated Cancer Center

 **D. DAN AND BETTY KAHN**  
HUMAN HEALTH BUILDING



supported by  
The Azrieli Foundation

Host  
**Prof. Amir Orian**  
Director, RTICC

# RTICC

## INTERNATIONAL GUEST SEMINAR

**14<sup>th</sup> July**  
**13:30-14:30**

 **4th Floor seminar Room, The Ruth and  
Bruce Rappaport Faculty of Medicine**

### “Resistance and Persistence in Cancer”

Cancer evolves by accumulating driver events that increase the fitness of the cells, starting from normal, to pre-cancerous expansions, to cancer, and, finally, to becoming resistant to therapy. Cancer cells can leverage different mechanisms to evade the therapeutic pressure and develop drug resistance. In some cases, a fraction of cancer cells tolerate the drug and persist during treatment. To delay or prevent resistance or persistence, one needs to map and understand these mechanisms which can then help identify targets for developing new drugs as well as guide therapeutic decisions.

I will discuss different approaches for finding mechanisms of resistance as well as our efforts to understand persistence. Both efforts involve understanding the evolutionary relationship of the cancer cells to detect recurrent events that drive resistance or persistence. I will give examples from studying resistance in breast cancer and persistence in lung cancer. Finally, I will demonstrate the benefit of using whole-genome sequencing data to further enrich the detection of resistance mechanisms.